.png){kind=icon}
返回
Complement-driven hemolytic uremic syndrome
.png){kind=icon}
OA
AI
DOI：10.1002/ajh.26854.png)
.png){kind=icon}
.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Overactivation of the complement alternative pathway drives the pathogenesis of primary atypical hemolytic uremic syndrome (aHUS). Genetically-determined or acquired dysregulation of the complement is frequently identified in patients with aHUS, pregnancy-related hemolytic uremic syndrome (HUS), and severe hypertension-associated HUS. In contrast, it is still unclear whether self-limited complement activation, which frequently occurs in other forms of HUS, provides key mechanistic clues or results from endothelial damage. Development of novel biomarkers is underway to firmly establish complement-driven pathogenesis. C5 blockade therapy has revolutionized the management of aHUS patients, resulting in a halving of the subpopulation under chronic dialysis over the course of a few years. On the other hand, the efficacy of C5 blockade in secondary forms of HUS, as assessed by small and uncontrolled case series, is less compelling and should be investigated through properly designed prospective clinical trials. The increased risk of meningococcal infection, related to C5 inhibition, must be rigorously addressed with suitable prophylaxis. Treatment duration should be determined based on an individualized benefit/risk assessment.
Keyword:
ANTIBODY-MEDIATED REJECTION
THROMBOTIC MICROANGIOPATHY
ADULT PATIENTS
MENINGOCOCCAL DISEASE
INHIBITOR ECULIZUMAB
ESCHERICHIA-COLI
GENE-MUTATIONS
ATYPICAL HUS
C5 INHIBITOR
WHOLE-BLOOD
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
9.9
论文数:
8.6K
被引数:
1.7W
机构
引用论文
分享收藏Complement System as a New Target for Hematopoietic Stem Cell Transplantation-Related Thrombotic Microangiopathy.png)
PHARMACEUTICALSOAAI
PHARMACEUTICALSIF4.8
OAAI分享收藏
查看更多内容